You have full text access to this OnlineOpen article

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

Anita V. Mitra¹,
Elizabeth K. Bancroft^1,2,
Yolanda Barbachano^1,2,
Elizabeth C. Page¹,
C. S. Foster³,
C. Jameson²,
G. Mitchell⁴,
G. J. Lindeman⁵,
A. Stapleton⁶,
G. Suthers⁷,
D. G. Evans⁸,
D. Cruger⁹,
I. Blanco¹⁰,
C. Mercer¹¹,
J. Kirk¹²,
L. Maehle¹³,
S. Hodgson¹⁴,
L. Walker¹⁵,
L. Izatt¹⁶,
F. Douglas¹⁷,
K. Tucker¹⁸,
H. Dorkins¹⁹,
V. Clowes²⁰,
A. Male²¹,
A. Donaldson²²,
C. Brewer²³,
R. Doherty⁴,
B. Bulman⁸,
P. J. Osther²⁴,
M. Salinas¹⁰,
D. Eccles¹¹,
K. Axcrona¹³,
I. Jobson¹⁷,
B. Newcombe²⁰,
C. Cybulski²⁴,
W. S. Rubinstein²⁶,
S. Buys²⁷,
S. Townshend²⁸,
E. Friedman²⁹,
S. Domchek³⁰,
T. Ramon y Cajal³¹,
A. Spigelman^32,33,
S. H. Teo^34,35,
N. Nicolai³⁶,
N. Aaronson³⁷,
A. Ardern-Jones²,
C. Bangma³⁸,
D. Dearnaley^1,2,
J. Eyfjord³⁹,
A. Falconer⁴⁰,
H. Grönberg⁴¹,
F. Hamdy⁴²,
O. Johannsson⁴³,
V. Khoo¹,
Z. Kote-Jarai¹,
H. Lilja⁴⁴,
J. Lubinski²⁵,
J. Melia¹,
C. Moynihan¹,
S. Peock⁴⁵,
G. Rennert⁴⁶,
F. Schröder³⁸,
P. Sibley⁴⁷,
M. Suri⁴⁸,
P. Wilson⁴⁹,
Y. J. Bignon⁵⁰,
S. Strom⁵¹,
M. Tischkowitz⁵²,
A. Liljegren⁵³,
D. Ilencikova⁵⁴,
A. Abele⁵⁵,
K. Kyriacou⁵⁶,
C. van Asperen⁵⁷,
L. Kiemeney⁵⁸,
The IMPACT Study Collaborators,
D. F. Easton⁴⁵,
Rosalind A. Eeles^1,2,*

Article first published online: 14 SEP 2010

DOI: 10.1111/j.1464-410X.2010.09648.x

Issue

BJU International

Volume 107, Issue 1, pages 28–39, January 2011

Additional Information

How to Cite

Mitra, A. V., Bancroft, E. K., Barbachano, Y., Page, E. C., Foster, C. S., Jameson, C., Mitchell, G., Lindeman, G. J., Stapleton, A., Suthers, G., Evans, D. G., Cruger, D., Blanco, I., Mercer, C., Kirk, J., Maehle, L., Hodgson, S., Walker, L., Izatt, L., Douglas, F., Tucker, K., Dorkins, H., Clowes, V., Male, A., Donaldson, A., Brewer, C., Doherty, R., Bulman, B., Osther, P. J., Salinas, M., Eccles, D., Axcrona, K., Jobson, I., Newcombe, B., Cybulski, C., Rubinstein, W. S., Buys, S., Townshend, S., Friedman, E., Domchek, S., Ramon y Cajal, T., Spigelman, A., Teo, S. H., Nicolai, N., Aaronson, N., Ardern-Jones, A., Bangma, C., Dearnaley, D., Eyfjord, J., Falconer, A., Grönberg, H., Hamdy, F., Johannsson, O., Khoo, V., Kote-Jarai, Z., Lilja, H., Lubinski, J., Melia, J., Moynihan, C., Peock, S., Rennert, G., Schröder, F., Sibley, P., Suri, M., Wilson, P., Bignon, Y. J., Strom, S., Tischkowitz, M., Liljegren, A., Ilencikova, D., Abele, A., Kyriacou, K., van Asperen, C., Kiemeney, L., The IMPACT Study Collaborators, Easton, D. F. and Eeles, R. A. (2011), Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU International, 107: 28–39. doi: 10.1111/j.1464-410X.2010.09648.x

Author Information

¹
The Institute of Cancer Research, Sutton, Surrey, UK
²
Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
³
Royal Liverpool University Hospital, Liverpool, UK
⁴
Peter MacCallum Cancer Center, Victoria, Australia
⁵
Royal Melbourne Hospital, Parkville, Victoria, Australia
⁶
Repatriation General Hospital, Daw Park, Adelaide, SA, Australia
⁷
Department of Paediatrics, University of Adelaide, SA, Australia
⁸
St Mary’s Hospital, CMFT, Manchester, UK
⁹
Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark
¹⁰
Catalonian Institute of Oncology, L’Hospitalet, Barcelona, Spain
¹¹
Wessex Clinical Genetics Service, The Princess Anne Hospital, Southampton, UK
¹²
Westmead Hospital, Westmead, Sydney, NSW, Australia
¹³
Norwegian Radium Hospital, Oslo, Norway
¹⁴
St George’s Hospital, Tooting, London, UK
¹⁵
Churchill Hospital, Headington, Oxford, UK
¹⁶
Guy’s Hospital, London, UK
¹⁷
Institute of Human Genetics, Newcastle, UK
¹⁸
Prince of Wales Hospital, Sydney, NSW, Australia
¹⁹
North West Thames Regional Genetics Service, Kennedy Galton Centre, North West London Hospitals NHS Trust, Harrow, UK
²⁰
Addenbrooke’s Hospital, Cambridge, UK
²¹
NE Thames Regional Genetics Service, Institute of Child Health, London, UK
²²
St Michael’s Hospital, Bristol, UK
²³
Royal Devon & Exeter Hospital, Exeter, UK
²⁴
Department of Urology, Fredericia and Kolding Hospital, Fredericia, Denmark
²⁵
International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
²⁶
Center for Medical Genetics, NorthShore University HealthSystem, Evanston, IL, USA
²⁷
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
²⁸
King Edward Memorial Hospital, Perth, WA, Australia
²⁹
Chaim Shema Medical Center, Tel-Hashomer, Israel
³⁰
Abramson Cancer Center, Philadelphia, PA, USA
³¹
Hospital de Sant Pau, Barcelona, Spain
³²
Hunter Genetics, Newcastle, NSW, Australia
³³
University of New South Wales, St Vincent’s Clinical School, Sydney, Australia
³⁴
Cancer Research Initiatives Foundation, Subang Jaya Medical Centre, Selangor Darul Ehsan, Malaysia
³⁵
University of Malaya, Kuala Lumpur, Malaysia
³⁶
Istituto Nazionale dei Tumori, Milano, Italy
³⁷
The Netherlands Cancer Institute, Amsterdam, The Netherlands
³⁸
Erasmus University Medical Center, Rotterdam, The Netherlands
³⁹
Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
⁴⁰
Imperial College Healthcare NHS Trust, London, London, UK
⁴¹
University Hospital, Umea, Sweden
⁴²
University of Oxford, John Radcliffe Hospital, Oxford, UK
⁴³
University Hospital of Iceland, Reykjavik, Iceland
⁴⁴
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
⁴⁵
Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratories, Cambridge, UK
⁴⁶
CHS National Cancer Control Center, Carmel Medical Center, Haifa, Israel
⁴⁷
Siemens Healthcare Diagnostics, Caernarfon, Gwynedd, UK
⁴⁸
Nottingham City Hospital, Nottingham, UK
⁴⁹
BioZenix, Altrincham, Cheshire, UK
⁵⁰
Center Jean Perrin, Laboratoire D’Oncologie Moléculaire, Clermont-Ferrand, France
⁵¹
The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
⁵²
McGill Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada
⁵³
Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
⁵⁴
National Cancer Institute, Bratislava, Slovak Republic
⁵⁵
Hereditary Cancer Institute, Riga Stradins University, Riga, Latvia
⁵⁶
The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
⁵⁷
Leiden University Medical Center K5-R, Leiden, The Netherlands
⁵⁸
Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

^*Rosalind Eeles, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. e-mail: rosalind.eeles@icr.ac.uk

Publication History

Issue published online: 23 DEC 2010
Article first published online: 14 SEP 2010
Accepted for publication 7 May 2010

ARTICLE TOOLS

View Full Article (HTML) Get PDF (458K)

REFERENCES

1
The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310–6
2
Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358–65
3
Schröder FH, Bangma CH. The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br J Urol 1997; 79 (Suppl. 1): 68–71
- PubMed,
- Web of Science® Times Cited: 65
4
Prorok PC, Andriole GL, Bresalier RS et al.; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21 (Suppl.): 273–309
- CrossRef,
- Web of Science® Times Cited: 113
5
Donovan J, Hamdy F, Neal D et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1–88
- PubMed,
- CAS
6
Andriole GL, Crawford ED, Grubb RL III et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310–9
7
Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320–8
8
Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009; 59: 27–41
Direct Link:
9
McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998; 159: 1368–72
10
Draisma G, De Koning HJ. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 2003; 92 (Suppl. 2): 106–11
Direct Link:
11
Mitra A, Fisher C, Foster CS et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008; 98: 502–7
12
Cuzick J, Fisher G, Kattan MW et al. Long-term outcome among men with conservatively treated localized prostate cancer. Br J Cancer 2006; 95: 1186–94
13
McWhorter WP, Hernandez AD, Meikle AW et al. A screening study of prostate cancer in high risk families. J Urol 1992; 148: 826–8
14
Narod SA, Dupont A, Cusan L et al. The impact of family history on early detection of prostate cancer. Nat Med 1995; 1: 99–101
15
Matikainen MP, Schleutker J, Morsky P, Kallioniemi OP, Tammela TL. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Clin Cancer Res 1999; 5: 1275–9
16
Mäkinen T, Tammela TL, Stenman UH et al. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002; 20: 2658–63
17
Valeri A, Cormier L, Moineau MP et al. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol 2002; 168: 483–7
18
Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. J Urol 2002; 168: 1980–3
19
Uzzo RG, Pinover WH, Horwitz EM et al. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination. Urology 2003; 61: 754–9
20
Horsburgh S, Matthew A, Bristow R, Trachtenberg J. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. Prostate 2005; 65: 124–9
Direct Link:
21
Bunker CH, Patrick AL, Konety BR et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev 2002; 11: 726–9
- PubMed,
- Web of Science® Times Cited: 44
22
Sartor O. Early detection of prostate cancer in African-American men with an increased familial risk of disease. J La State Med Soc 1996; 148: 179–85
- PubMed,
- CAS
23
Kiemeney LA, Broeders MJ, Pelger M et al. Screening for prostate cancer in Dutch hereditary prostate cancer families. Int J Cancer 2008; 122: 871–6
Direct Link:
24
Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 929–35
25
Narod SA, Neuhausen S, Vichodez G et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008; 99: 371–4
26
Lehrer S, Fodor F, Stock RG et al. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998; 78: 771–3
27
Nastiuk KL, Mansukhani M, Terry MB et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999; 40: 172–7
Direct Link:
28
Hubert A, Peretz T, Manor O et al. The Jewish Ashkenazi founder mutation in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 1999; 65: 921–4
29
Vazina A, Baniel J, Yaacobi Y et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer in Israel. Br J Cancer 2000; 83: 463–6
30
Giusti RM, Rutter JL, Duray PH et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 2003; 40: 787–92
31
Mitra AV, Bancroft EK, Eeles RA, IMPACT Steering Committee and Collaborators. A review of targeted screening for prostate cancer: introducing the IMPACT study. BJU Int 2007; 99: 1350–5
Direct Link:
32
Berney DM, Fisher G, Kattan MW et al. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 2007; 100: 1240–4
Direct Link:
33
National Institute of Health and Clinical Excellence. Prostate cancer: diagnosis and treatment guideline. 2008. Available at: http://www.nice.org.uk/CG058. Accessed 1 October 2009
34
Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106–31
35
Green FL. AJCC Cancer Staging Manual. Chicago: Springer, 2002
- CrossRef
36
Lamerato LE, Marcus PM, Jacobsen G, Johnson CC. Recruitment in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: the First Phase of Recruitment at Henry Ford Health System. Cancer Epidemiol Biomarkers Prev 2008; 17: 827–33
37
Melia J, Dearnaley D, Moss S et al. The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk. Br J Cancer 2006; 94: 499–506
38
Roobol MJ, Schröder FH, Kranse R. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 2006; 66: 604–12
Direct Link:
39
Liede A, Metcalfe K, Hanna D et al. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet 2000; 67: 1494–504
40
Brooks L, Lennard F, Shenton A et al. BRCA1/2 predictive testing: a study of uptake in two centers. Eur J Hum Genet 2004; 12: 654–62
41
Evans DGR, Binchy A, Shenton A, Hopwood P, Craufurd D. Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives. Clin Genet 2009; 75: 124–32
Direct Link:
42
McAllister MF, Evans DG, Ormiston W, Daly P. Men in breast cancer families: a preliminary qualitative study of awareness and experience. J Med Genet 1998; 35: 739–44
43
Meiser B, Cowan R, Costello A, Giles GG, Lindeman GJ, Gaff CL. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men’s screening uptake. Urology 2007; 70: 738–42
44
Roobol MJ, Zappa M, Maattanen L, Ciatto S. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 2007; 67: 439–46
Direct Link:
45
Postma R, Schröder FH, van Leenders GJ et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) – Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52: 89–97
46
Khan MA, Partin AW, Rittenhouse HG et al. Evaluation of pro-prostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0–10.0 ng/mL. J Urol 2003; 170: 723–6
47
Billis A, Meirelles L, Freitas LL, Magna LA, Ferreira U. Does the type of prostatic atrophy influence the association of extent of atrophy in needle biopsies and serum prostate-specific antigen levels? Urology 2009; 74: 1111–5
48
Verhamme KM, Dieleman JP, Bleumink GS et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care – the Triumph project. Eur Urol 2002; 42: 323–8
49
Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860–4
50
Schröder FH, Carter HB, Wolters T et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008; 53: 468–77
51
Schröder FH, Roobol MJ, Van Leenders GJLH, Bangma CH. Should men age 55-74 presenting with PSA <3.0 ng/ml be biopsied to diagnose prostate cancer? Eur Urol Suppl 2007; 6: 222
- CrossRef,
- Web of Science®
52
Cancer Research UK 2009. Available at: http://www.cancerresearchuk.org/cancerstats/types/prostate/incidence. Accessed 1 October 2009
53
Australia’s Health 2004. Available at: http://www.aihw.gov.au. Accessed 1 October 2009
54
Howard K, Barratt A, Mann GJ, Patel MI. A model of prostate-specific antigen screening outcomes for low to High Risk Men. Arch Intern Med 2009; 169 (17): 1603–10

View Full Article (HTML) Get PDF (458K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

BJU International

How to Cite

Author Information

Publication History

ARTICLE TOOLS

REFERENCES

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

BJU International

How to Cite

Author Information

Publication History

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

REFERENCES

More content like this